Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis
出版年份 2015 全文链接
标题
Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis
作者
关键词
-
出版物
ANNALS OF THE RHEUMATIC DISEASES
Volume 75, Issue 5, Pages 883-890
出版商
BMJ
发表日期
2015-04-10
DOI
10.1136/annrheumdis-2014-207109
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Orphan nuclear receptor NR4A1 regulates transforming growth factor-β signaling and fibrosis
- (2015) Katrin Palumbo-Zerr et al. NATURE MEDICINE
- Stimulation of the soluble guanylate cyclase (sGC) inhibits fibrosis by blocking non-canonical TGFβ signalling
- (2014) Christian Beyer et al. ANNALS OF THE RHEUMATIC DISEASES
- Combined inhibition of morphogen pathways demonstrates additive antifibrotic effects and improved tolerability
- (2014) Alfiya Distler et al. ANNALS OF THE RHEUMATIC DISEASES
- Inhibition of casein kinase II reduces TGFβ induced fibroblast activation and ameliorates experimental fibrosis
- (2014) Yun Zhang et al. ANNALS OF THE RHEUMATIC DISEASES
- S100A4 amplifies TGF-β-induced fibroblast activation in systemic sclerosis
- (2014) Michal Tomcik et al. ANNALS OF THE RHEUMATIC DISEASES
- Activation of liver X receptors inhibits experimental fibrosis by interfering with interleukin-6 release from macrophages
- (2014) Christian Beyer et al. ANNALS OF THE RHEUMATIC DISEASES
- Vitamin D receptor regulates TGF-β signalling in systemic sclerosis
- (2014) Pawel Zerr et al. ANNALS OF THE RHEUMATIC DISEASES
- Nintedanib: First Global Approval
- (2014) Paul L. McCormack DRUGS
- Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
- (2014) Luca Richeldi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combination therapy: the future of management for idiopathic pulmonary fibrosis?
- (2014) Wim A Wuyts et al. Lancet Respiratory Medicine
- Heat shock protein 90 (Hsp90) inhibition targets canonical TGF-β signalling to prevent fibrosis
- (2013) Michal Tomcik et al. ANNALS OF THE RHEUMATIC DISEASES
- The search for theperfect animal modeldiscloses the importance of biological targets for the treatment of systemic sclerosis
- (2013) Francesco Del Galdo et al. ANNALS OF THE RHEUMATIC DISEASES
- Vascular endothelial growth factor aggravates fibrosis and vasculopathy in experimental models of systemic sclerosis
- (2013) Britta Maurer et al. ANNALS OF THE RHEUMATIC DISEASES
- Blockade of canonical Wnt signalling ameliorates experimental dermal fibrosis
- (2013) Christian Beyer et al. ANNALS OF THE RHEUMATIC DISEASES
- Levels of target activation predict antifibrotic responses to tyrosine kinase inhibitors
- (2013) Britta Maurer et al. ANNALS OF THE RHEUMATIC DISEASES
- 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative
- (2013) Frank van den Hoogen et al. ANNALS OF THE RHEUMATIC DISEASES
- Combined Inhibition of c-Abl and PDGF Receptors for Prevention and Treatment of Murine Sclerodermatous Chronic Graft-versus-Host Disease
- (2012) Pawel Zerr et al. AMERICAN JOURNAL OF PATHOLOGY
- Inhibition of hedgehog signalling prevents experimental fibrosis and induces regression of established fibrosis
- (2012) Angelika Horn et al. ANNALS OF THE RHEUMATIC DISEASES
- Jun N-terminal kinase as a potential molecular target for prevention and treatment of dermal fibrosis
- (2012) Nicole Reich et al. ANNALS OF THE RHEUMATIC DISEASES
- Pomalidomide is effective for prevention and treatment of experimental skin fibrosis
- (2012) Simon Weingärtner et al. ANNALS OF THE RHEUMATIC DISEASES
- JAK-2 as a novel mediator of the profibrotic effects of transforming growth factor β in systemic sclerosis
- (2012) Clara Dees et al. ARTHRITIS AND RHEUMATISM
- Inhibition of hedgehog signaling for the treatment of murine sclerodermatous chronic graft-versus-host disease
- (2012) P. Zerr et al. BLOOD
- Activation of canonical Wnt signalling is required for TGF-β-mediated fibrosis
- (2012) Alfiya Akhmetshina et al. Nature Communications
- The transcription factor JunD mediates transforming growth factor -induced fibroblast activation and fibrosis in systemic sclerosis
- (2011) K. Palumbo et al. ANNALS OF THE RHEUMATIC DISEASES
- Inhibition of Notch signaling prevents experimental fibrosis and induces regression of established fibrosis
- (2011) Clara Dees et al. ARTHRITIS AND RHEUMATISM
- Fibroblast abnormalities in the pathogenesis of systemic sclerosis
- (2011) Alicia Usategui et al. Expert Review of Clinical Immunology
- Platelet-derived serotonin links vascular disease and tissue fibrosis
- (2011) Clara Dees et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database
- (2010) A. J. Tyndall et al. ANNALS OF THE RHEUMATIC DISEASES
- Animal models of systemic sclerosis: Prospects and limitations
- (2010) Christian Beyer et al. ARTHRITIS AND RHEUMATISM
- Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis
- (2009) Alfiya Akhmetshina et al. ARTHRITIS AND RHEUMATISM
- Increased PDGFRα Activation Disrupts Connective Tissue Development and Drives Systemic Fibrosis
- (2009) Lorin E. Olson et al. DEVELOPMENTAL CELL
- Scleroderma
- (2009) Armando Gabrielli et al. NEW ENGLAND JOURNAL OF MEDICINE
- Src kinases in systemic sclerosis: Central roles in fibroblast activation and in skin fibrosis
- (2008) Catherine Skhirtladze et al. ARTHRITIS AND RHEUMATISM
- BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
- (2008) F. Hilberg et al. CANCER RESEARCH
- Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis
- (2008) Alfiya Akhmetshina et al. FASEB JOURNAL
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started